HK1202373A1 - Animal models and therapeutic molecules - Google Patents

Animal models and therapeutic molecules

Info

Publication number
HK1202373A1
HK1202373A1 HK15102886.6A HK15102886A HK1202373A1 HK 1202373 A1 HK1202373 A1 HK 1202373A1 HK 15102886 A HK15102886 A HK 15102886A HK 1202373 A1 HK1202373 A1 HK 1202373A1
Authority
HK
Hong Kong
Prior art keywords
animal models
therapeutic molecules
therapeutic
molecules
models
Prior art date
Application number
HK15102886.6A
Other languages
English (en)
Chinese (zh)
Inventor
Allan Bradley
E-Chiang Lee
Qi Liang
Wei Wang
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43428834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1202373(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0911846.4A external-priority patent/GB0911846D0/en
Priority claimed from GB0913102A external-priority patent/GB0913102D0/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of HK1202373A1 publication Critical patent/HK1202373A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1239—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Vibrionaceae (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15102886.6A 2009-07-08 2012-03-14 Animal models and therapeutic molecules HK1202373A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22396009P 2009-07-08 2009-07-08
GBGB0911846.4A GB0911846D0 (en) 2009-07-08 2009-07-08 Animal models and therapeutic molecules
GB0913102A GB0913102D0 (en) 2009-07-28 2009-07-28 Animal models and therapeutic molesules
US35566610P 2010-06-17 2010-06-17

Publications (1)

Publication Number Publication Date
HK1202373A1 true HK1202373A1 (en) 2015-10-02

Family

ID=43428834

Family Applications (5)

Application Number Title Priority Date Filing Date
HK12113213.0A HK1172207A1 (zh) 2009-07-08 2012-03-14 動物模型及治療分子
HK13107869.8A HK1180535A1 (en) 2009-07-08 2012-03-14 Animal models and therapeutic molecules
HK12102592.4A HK1162119A1 (en) 2009-07-08 2012-03-14 Animal models and therapeutic molecules
HK15102886.6A HK1202373A1 (en) 2009-07-08 2012-03-14 Animal models and therapeutic molecules
HK15101569.2A HK1201026A1 (en) 2009-07-08 2012-03-14 Animal models and therapeutic molecules

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HK12113213.0A HK1172207A1 (zh) 2009-07-08 2012-03-14 動物模型及治療分子
HK13107869.8A HK1180535A1 (en) 2009-07-08 2012-03-14 Animal models and therapeutic molecules
HK12102592.4A HK1162119A1 (en) 2009-07-08 2012-03-14 Animal models and therapeutic molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15101569.2A HK1201026A1 (en) 2009-07-08 2012-03-14 Animal models and therapeutic molecules

Country Status (23)

Country Link
US (33) US20120204278A1 (ja)
EP (19) EP2421357B1 (ja)
JP (7) JP5944312B2 (ja)
KR (1) KR101875233B1 (ja)
CN (2) CN102638971B (ja)
AU (4) AU2010269978B2 (ja)
BR (1) BR112012000536A2 (ja)
CA (1) CA2767436A1 (ja)
CY (1) CY1126083T1 (ja)
DK (12) DK3028565T3 (ja)
ES (7) ES2965212T3 (ja)
HK (5) HK1172207A1 (ja)
HR (2) HRP20130253T1 (ja)
HU (2) HUE055817T2 (ja)
LT (1) LT3241435T (ja)
NO (1) NO2792236T3 (ja)
NZ (1) NZ597481A (ja)
PL (4) PL2564695T3 (ja)
PT (4) PT3241435T (ja)
SG (2) SG2014010995A (ja)
SI (2) SI2421357T1 (ja)
SM (1) SMT201300046B (ja)
WO (1) WO2011004192A1 (ja)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP2421357B1 (en) * 2009-07-08 2013-01-23 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
RU2724663C2 (ru) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
AU2011234988B2 (en) 2010-03-31 2014-10-30 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
CA2802591A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
MY195212A (en) * 2010-06-22 2023-01-11 Regeneron Pharma Mice Expressing an Immunoglobulin Hybrid Light Chain
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10881084B2 (en) 2010-07-26 2021-01-05 Trianni, Inc Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2947151A1 (en) 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
DE14176593T1 (de) * 2011-02-25 2015-03-05 Regeneron Pharmaceuticals, Inc. ADAM6 Mäuse
AU2012225310B2 (en) 2011-03-09 2017-08-03 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
WO2013006688A2 (en) 2011-07-05 2013-01-10 Duke University N-terminal deleted gp120 immunogens
SI2739740T1 (sl) * 2011-08-05 2019-12-31 Regeneron Pharmaceuticals, Inc. Humanizirane univerzalne lahkoverižne miši
GB2501753A (en) * 2012-05-04 2013-11-06 Kymab Ltd Human antibodies
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
GB2495083A (en) * 2011-09-26 2013-04-03 Kymab Ltd Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates
US10092638B2 (en) 2011-10-03 2018-10-09 Duke University GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus
SI2627773T1 (sl) * 2011-10-17 2017-12-29 Regeneron Pharmaceuticals, Inc., Omejena težka veriga imunoglobulinov pri miših
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
PL3424947T3 (pl) * 2011-10-28 2021-06-14 Regeneron Pharmaceuticals, Inc. Myszy z genetycznie zmodyfikowanym receptorem komórek t
KR101926442B1 (ko) 2011-10-28 2018-12-12 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
RS56656B1 (sr) 2011-10-28 2018-03-30 Regeneron Pharma Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
EP2793567B1 (en) * 2011-12-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
CN104202971B (zh) 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
RU2683514C2 (ru) * 2012-03-06 2019-03-28 Регенерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CA2865645A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Non-human animals expressing immunoglobulin sequences ph-sensitive for antigen building
SI2883449T1 (en) 2012-03-16 2018-05-31 Regeneron Pharmaceuticals, Inc. Light-chain modified antibodies with histidine and genetically modified rodents for their production
EP2825035A1 (en) 2012-03-16 2015-01-21 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
NZ717848A (en) * 2012-06-12 2019-03-29 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
AU2013296182B2 (en) 2012-08-03 2018-03-08 Sab, Llc Complex chromosome engineering for production of human antibodies in transgenic animals
DK3653049T3 (da) * 2012-12-14 2023-11-13 Omniab Inc Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse
MX357061B (es) 2013-02-06 2018-06-25 Regeneron Pharma Diseño de inmunogenos a base de linaje de celulas b con animales humanizados.
KR102579405B1 (ko) * 2013-02-20 2023-09-18 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
CN104994730B (zh) 2013-02-20 2018-12-28 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
DK2958937T3 (en) 2013-02-22 2018-11-26 Regeneron Pharma Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
ES2681622T3 (es) 2013-09-18 2018-09-14 Kymab Limited Métodos, células y organismos
TW201546284A (zh) 2013-10-01 2015-12-16 Kymab Ltd 動物模式及治療分子
RU2685914C1 (ru) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
SG11201609634YA (en) * 2014-06-06 2016-12-29 Regeneron Pharma Methods and compositions for modifying a targeted locus
FI3169778T3 (fi) * 2014-07-14 2023-12-13 Univ Washington State Ituradan soluja ablatoiva nanos-geeninpoisto
SG11201701040XA (en) 2014-09-19 2017-03-30 Regeneron Pharma Chimeric antigen receptors
GB201418713D0 (en) 2014-10-21 2014-12-03 Kymab Ltd Bindings Proteins
US10362771B2 (en) * 2014-11-20 2019-07-30 Kyoto University Method for knock-in of DNA into target region of mammalian genome, and cell
PT3265123T (pt) 2015-03-03 2023-02-01 Kymab Ltd Anticorpos, usos e métodos
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
AU2016246698B2 (en) 2015-04-06 2022-06-02 Regeneron Pharmaceuticals, Inc. Humanized T cell mediated immune responses in non-human animals
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
JP6929877B2 (ja) 2016-02-04 2021-09-01 トリアニ・インコーポレイテッドＴｒｉａｎｎｉ， Ｉｎｃ． 免疫グロブリン産生の増強
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
WO2017163049A1 (en) 2016-03-21 2017-09-28 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
PT3462853T (pt) 2016-06-03 2023-04-21 Regeneron Pharma Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
AU2017281830B2 (en) 2016-06-20 2023-04-06 Kymab Limited Anti-PD-L1 antibodies
EP3497128A2 (en) 2016-08-09 2019-06-19 Kymab Limited Anti-icos antibodies
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
PT3407709T (pt) * 2016-11-04 2020-08-20 Regeneron Pharma Animais não humanos possuindo um lócus da cadeia leve lambda de immunoglobulina modificada
PE20191497A1 (es) 2016-12-21 2019-10-21 Cephalon Inc Anticuerpos que se unen especificamente a il-15 humana y usos de estos
SG11201906540WA (en) 2017-01-19 2019-08-27 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
WO2018152285A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
PE20191551A1 (es) 2017-02-17 2019-10-24 Denali Therapeutics Inc Polipeptidos de union al receptor de transferrina disenados
GB2561352B (en) * 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
JP2020516590A (ja) 2017-04-14 2020-06-11 コールド ジェネシス， インコーポレイテッド 膀胱癌の治療方法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
US11370842B2 (en) 2017-08-01 2022-06-28 City Of Hope Anti-IL1RAP antibodies
AU2018351072B2 (en) * 2017-10-20 2024-08-22 Fred Hutchinson Cancer Center Systems and methods to produce B cells genetically modified to express selected antibodies
ES2928995T3 (es) 2017-12-05 2022-11-24 Regeneron Pharma Ratones que tienen una cadena ligera lambda de inmunoglobulina genomanipulada y usos de los mismos
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
BR112020019026A2 (pt) 2018-03-24 2020-12-29 Regeneron Pharmaceuticals, Inc. Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana
SG11202008620VA (en) 2018-03-26 2020-10-29 Regeneron Pharma Humanized rodents for testing therapeutic agents
CN108486125B (zh) * 2018-03-27 2024-01-05 重庆金迈博生物科技有限公司 一种核酸分子及其在制备人源单域抗体中的应用
CN108486126A (zh) * 2018-03-27 2018-09-04 重庆金迈博生物科技有限公司 一种核酸分子及其在人源化抗体中的应用
MX2020013652A (es) 2018-06-14 2022-04-21 Regeneron Pharma Animales no humanos con capacidad de reordenamiento dh-dh en las secuencias codificantes de la cadena pesada de inmunoglobulina.
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
JP2022528721A (ja) 2019-04-09 2022-06-15 アブクロ，インク． キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）除去抗体
US20230025129A1 (en) 2019-11-29 2023-01-26 Kymab Limited Treatment for physiological iron overload
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CN115667532A (zh) 2020-06-02 2023-01-31 百奥赛图(北京)医药科技股份有限公司 具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
WO2021261620A1 (ko) 2020-06-25 2021-12-30 주식회사 휴맵 이형접합성 형질전환 동물
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
KR20230084157A (ko) 2020-10-08 2023-06-12 주식회사 휴맵 인간화 면역글로불린 유전자좌를 포함하는 게놈을 가지는 형질전환 비인간-동물 제조방법
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
JP2024528877A (ja) 2021-07-26 2024-08-01 アブクロ，インク． キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）枯渇性抗体
WO2023097236A1 (en) * 2021-11-24 2023-06-01 The Rockefeller University Compositions and methods for generating immunoglobulin knock-in mice
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US114985A (en) * 1871-05-16 Improvement in apparatus for cooling and preserving milk and other liquids
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4720449A (en) 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
AU2515992A (en) * 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5859307A (en) 1992-02-04 1999-01-12 Massachusetts Institute Of Technology Mutant RAG-1 deficient animals having no mature B and T lymphocytes
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
JP4242447B2 (ja) 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
DE4331162A1 (de) 1993-09-14 1995-03-16 Bayer Ag Verfahren zur Herstellung von Cyaninfarbstoffen
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU3507297A (en) 1996-06-26 1998-01-14 Baylor College Of Medicine Chromosomal rearrangement by insertion of two recombination substrates
JP2000515002A (ja) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20020088019A1 (en) 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
EP1574573B9 (en) 1997-11-18 2009-03-04 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
ATE449844T1 (de) 1997-12-05 2009-12-15 Europ Lab Molekularbiolog Neue methode zur klonierung dns unter anwendung des e. coli rece/rect rekombinationssystems
EP0939120A1 (en) 1998-02-27 1999-09-01 Gesellschaft für biotechnologische Forschung mbH (GBF) Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU5867100A (en) 1999-05-03 2000-12-12 Medarex, Inc. Human antibodies to staphylococcus aureus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6355412B1 (en) 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2307503A1 (en) * 2000-05-02 2001-11-02 Carlos F. Barbas Iii Peptides for use as a vaccine or treatment for hiv infection
EP1309709A2 (en) * 2000-07-21 2003-05-14 The United States of America, represented by The Secretary of Agriculture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002219841A1 (en) * 2000-11-16 2002-05-27 Cornell Research Foundation Inc. Vectors for conditional gene inactivation
DE60138832D1 (de) 2000-11-17 2009-07-09 Kyowa Hakko Kirin Co Ltd Expression xenogener (menschlicher) immunglobuline in geklonten, transgenen rindern
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US20030093818A1 (en) * 2000-12-19 2003-05-15 Belmont Heather J. Transgenic animals comprising a humanized immune system
WO2002053596A2 (en) 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
AUPR446701A0 (en) 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
JP2003000243A (ja) 2001-06-25 2003-01-07 Takachika Azuma 変異体の製造法
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US6891209B2 (en) 2001-08-13 2005-05-10 Amberwave Systems Corporation Dynamic random access memory trench capacitors
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
AU2003214842A1 (en) 2002-01-17 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
DK1523496T3 (da) 2002-07-18 2011-10-17 Merus B V Rekombinant fremstilling af blanding af antistoffer
AU2003278790A1 (en) 2002-09-09 2004-03-29 California Institute Of Technology Methods and compositions for the generation of humanized mice
CA2501981A1 (en) 2002-10-01 2004-04-15 Mitos Pharmaceuticals, Inc. Nitroxide radioprotector formulations and methods of use
US7700356B2 (en) * 2002-11-08 2010-04-20 The United States Of America As Represented By The Secretary Of Agriculture System for gene targeting and producing stable genomic transgene insertions
DE10251918A1 (de) * 2002-11-08 2004-05-19 Horn, Carsten, Dipl.-Biochem. Dr. Systeme zur Erzeugung stabiler genomischer Transgen-Insertionen
AR042145A1 (es) 2002-11-27 2005-06-08 Dow Agrociences Llc Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
CN1326878C (zh) * 2003-04-29 2007-07-18 中国抗体制药有限公司 抗人非何杰金淋巴瘤嵌合抗体及其衍生物与应用
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US7205148B2 (en) 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
GB2403475B (en) † 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
MXPA06000562A (es) 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
US7663017B2 (en) * 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
US7604994B2 (en) 2003-09-03 2009-10-20 Morphotek, Inc. Genetically altered antibody-producing cell lines with improved antibody characteristics
CA2445602C (en) 2003-10-20 2014-01-14 Campusgen Gmbh Nucleotide sequence for creatinine deiminase and method of use
CN102838675B (zh) 2003-12-10 2014-07-30 梅达雷克斯有限责任公司 Ip-10抗体及其用途
MXPA06010673A (es) 2004-03-19 2007-06-20 Amgen Inc Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
EP1978032A3 (en) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
FR2875239B1 (fr) 2004-09-10 2007-07-20 Inst Necker Ass Loi De 1901 Procede pour l'acceleration des mutations somatiques et son application en proteomique
WO2006029459A1 (en) 2004-09-13 2006-03-23 Evogenix, Inc Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof
WO2006044492A2 (en) 2004-10-14 2006-04-27 Ingenious Targeting Laboratory, Inc. Methods for generating rat embryo-derived cell lines and genetic modification of rat genome
CA2827654C (en) † 2004-10-19 2019-04-02 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
CA2584814A1 (en) 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglobulin expression in non-human transgenic animals
WO2006055704A2 (en) 2004-11-17 2006-05-26 Curagen Corporation Antibodies directed to ten-m proteins and uses thereof
RU2394839C2 (ru) 2004-12-21 2010-07-20 Астразенека Аб Антитела против ангиопоэтина-2 и их применение
CA2604440A1 (en) 2005-04-29 2006-11-09 Inserm (Institut De La Sante Et De La Recherche Medicale) Transgenic animals and methods of making recombinant antibodies
BRPI0520212A2 (pt) 2005-05-14 2009-08-18 Univ Fudan métodos de geração de um vertebrado não humano transgênico, e de uma célula de vertebrado recombinante, célula de vertebrado em cultura, e, ácido nucleico
EP1780272A1 (en) 2005-10-27 2007-05-02 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method for enhancing somatic hypermutation, gene conversion and class switch recombination
GB0601513D0 (en) 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
SG169348A1 (en) * 2006-01-25 2011-03-30 Univ Erasmus Medical Ct Generation of heavy-chain only antibodies in transgenic animals
US7462759B2 (en) 2006-02-03 2008-12-09 Pioneer Hi-Bred International, Inc. Brittle stalk 2 gene family and related methods and uses
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
CA2655344C (en) * 2006-06-27 2016-09-13 Vaxdesign Corporation Models for vaccine assessment
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
US8084024B2 (en) 2006-08-22 2011-12-27 G2 Inflammation Pty Ltd Method for producing antibodies
US7778624B2 (en) * 2006-09-01 2010-08-17 Wanda Ying Li Outdoor umbrella with audio system
MX2009003393A (es) 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
WO2008070367A2 (en) * 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700194D0 (en) 2007-01-05 2007-02-14 Univ Edinburgh Humanisation of animals
JP2010520748A (ja) 2007-02-20 2010-06-17 アナプティスバイオ インコーポレイティッド 体細胞超変異系
EP2125889B1 (en) 2007-02-21 2014-01-15 University of Massachusetts Human antibodies against hepatitis c virus (hcv) uses thereof
WO2008118970A2 (en) 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
CA2688834C (en) 2007-06-01 2020-01-07 Ronald Buelow Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
MY147651A (en) 2007-07-31 2012-12-31 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
KR101709488B1 (ko) 2007-08-10 2017-02-24 리제너론 파아마슈티컬스, 인크. 인간 신경성장인자에 대한 고친화성 인간 항체
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
EP2592148B1 (en) * 2007-10-12 2018-09-12 F. Hoffmann-La Roche AG Protein expression from multiple nucleic acids
KR20100103810A (ko) 2007-12-10 2010-09-28 알리바 바이오파마수티컬스, 아이엔씨. 동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
US8227577B2 (en) * 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN101978000A (zh) 2008-01-25 2011-02-16 卡伯特公司 制备改性有色颜料的方法
KR101409375B1 (ko) 2008-01-31 2014-06-18 삼성전자주식회사 반도체 메모리장치의 블록 디코딩 회로
WO2009118524A2 (en) 2008-03-26 2009-10-01 Iti Scotland Limited Efficient insertion of dna into embryonic stem cells
WO2009129247A2 (en) 2008-04-14 2009-10-22 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
US20110123527A1 (en) * 2008-05-23 2011-05-26 Hiroaki Shizuya Method of generating single vl domain antibodies in transgenic animals
EP3456190B1 (en) 2008-06-27 2021-11-24 Merus N.V. Antibody producing transgenic murine animal
DK2346994T3 (da) * 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN102292445A (zh) 2008-12-18 2011-12-21 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
US9085795B2 (en) 2009-02-04 2015-07-21 Molecular Innovations, Inc. Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
EP2401298A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
WO2010113039A1 (en) 2009-04-03 2010-10-07 Medical Research Council Mutants of activation-induced cytidine deaminase (aid) and methods of use
TWI560271B (en) 2009-06-26 2016-12-01 Sealane Biotechnologies Llc Expression of surrogate light chains
GB0913102D0 (en) 2009-07-28 2009-09-02 Genome Res Ltd Animal models and therapeutic molesules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
GB0911846D0 (en) 2009-07-08 2009-08-19 Genome Res Ltd Animal models and therapeutic molecules
EP2421357B1 (en) 2009-07-08 2013-01-23 Kymab Limited Animal models and therapeutic molecules
AU2010271583B2 (en) 2009-07-15 2015-02-12 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2464220A4 (en) 2009-08-13 2014-05-07 Crystal Bioscience Inc Transgenic animal for the production of antibodies with minimal complementarity-determining regions
EP2496706A4 (en) 2009-11-05 2013-07-17 Anaptysbio Inc PROCESS FOR PREPARING IMPROVED ANTIGEN BINDING OF THE CHAIN FORMING AND OPTIONAL SOMATIC HYPERMUTATION
JP5796846B2 (ja) 2009-11-17 2015-10-21 エスエービー エルエルシー ヒト人工染色体ベクター
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
PL2954779T3 (pl) 2009-12-10 2019-07-31 Regeneron Pharmaceuticals, Inc. Myszy wytwarzające przeciwciała ciężkołańcuchowe
RU2724663C2 (ru) * 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
CN103025344B (zh) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 新型dna-结合蛋白及其用途
CA2802591A1 (en) 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
MY195212A (en) 2010-06-22 2023-01-11 Regeneron Pharma Mice Expressing an Immunoglobulin Hybrid Light Chain
EP2947151A1 (en) 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
TW201307391A (zh) 2010-12-22 2013-02-16 Genentech Inc 抗－ｐｃｓｋ９抗體及其使用方法
DE14176593T1 (de) 2011-02-25 2015-03-05 Regeneron Pharmaceuticals, Inc. ADAM6 Mäuse
SI2739740T1 (sl) 2011-08-05 2019-12-31 Regeneron Pharmaceuticals, Inc. Humanizirane univerzalne lahkoverižne miši
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
SI2627773T1 (sl) 2011-10-17 2017-12-29 Regeneron Pharmaceuticals, Inc., Omejena težka veriga imunoglobulinov pri miših
US20130102031A1 (en) 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20180295821A1 (en) 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
EP2793567B1 (en) 2011-12-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
CN104202971B (zh) 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
SG10201610123UA (en) 2012-03-02 2017-01-27 Regeneron Pharma Human antibodies to clostridium difficile toxins
RU2683514C2 (ru) 2012-03-06 2019-03-28 Регенерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
EP2825035A1 (en) 2012-03-16 2015-01-21 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
SI2800811T1 (sl) 2012-05-25 2017-10-30 The Regents Of The University Of California Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja
US8518765B1 (en) 2012-06-05 2013-08-27 Intermolecular, Inc. Aqua regia and hydrogen peroxide HCl combination to remove Ni and NiPt residues
NZ717848A (en) 2012-06-12 2019-03-29 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
US8962913B2 (en) * 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
CN105746362B (zh) 2012-11-09 2018-08-28 深圳市作物分子设计育种研究院 一种育性基因及其应用
MX2015007550A (es) 2012-12-12 2017-02-02 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
CN104994730B (zh) 2013-02-20 2018-12-28 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) * 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US20150033372A1 (en) 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US20140331344A1 (en) 2013-05-03 2014-11-06 Kymab Ltd. Transgenic Animals
US20140331339A1 (en) 2013-05-03 2014-11-06 Kymab Limited Transgenic Non-Human Assay Vertebrates, Assays and Kits
TW201546284A (zh) 2013-10-01 2015-12-16 Kymab Ltd 動物模式及治療分子
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
JP7087648B2 (ja) * 2018-05-08 2022-06-21 トヨタ自動車株式会社 電池パック

Also Published As

Publication number Publication date
EP2792236A2 (en) 2014-10-22
EP2604111A3 (en) 2013-12-18
US11812731B2 (en) 2023-11-14
DK2517557T3 (en) 2016-05-30
CN105340834A (zh) 2016-02-24
EP2604110B1 (en) 2016-11-30
DK2798950T4 (da) 2023-05-15
HK1172207A1 (zh) 2013-04-19
US20150113669A1 (en) 2015-04-23
EP3622813B1 (en) 2021-02-17
CN105340834B (zh) 2018-11-06
AU2018206729A1 (en) 2018-08-02
US9434782B2 (en) 2016-09-06
PL2421357T3 (pl) 2013-07-31
US20170105396A1 (en) 2017-04-20
DK2517556T3 (en) 2016-01-11
JP6612275B2 (ja) 2019-11-27
PL2564695T3 (pl) 2015-10-30
EP2604110A3 (en) 2013-08-14
JP6876853B2 (ja) 2021-05-26
EP3871497C0 (en) 2024-02-28
EP2517557B2 (en) 2023-08-02
EP3888457A1 (en) 2021-10-06
DK2421357T3 (da) 2013-04-15
US20170099817A1 (en) 2017-04-13
BR112012000536A2 (pt) 2020-08-11
US20170099815A1 (en) 2017-04-13
EP4215043A1 (en) 2023-07-26
HRP20130253T1 (hr) 2013-05-31
SI2421357T1 (sl) 2013-06-28
US20200352144A1 (en) 2020-11-12
AU2018206729B2 (en) 2020-10-08
PL3241435T3 (pl) 2021-12-13
DK3622815T3 (da) 2023-06-26
PT2517556E (pt) 2016-01-20
ES2974417T3 (es) 2024-06-27
PT2564695E (pt) 2015-06-03
EP2421357A1 (en) 2012-02-29
US20170094956A1 (en) 2017-04-06
US20230270088A1 (en) 2023-08-31
HUE055817T2 (hu) 2021-12-28
US20120204278A1 (en) 2012-08-09
US20140150126A1 (en) 2014-05-29
JP2020150951A (ja) 2020-09-24
US20140134156A1 (en) 2014-05-15
JP7141427B2 (ja) 2022-09-22
US20130318643A1 (en) 2013-11-28
EP3028564A1 (en) 2016-06-08
AU2021200079B2 (en) 2023-11-09
AU2016244326A1 (en) 2016-11-03
SG2014010995A (en) 2014-05-29
EP2517557B1 (en) 2016-04-13
CN102638971A (zh) 2012-08-15
SMT201300046B (it) 2013-07-09
EP2604111A2 (en) 2013-06-19
EP4014729B1 (en) 2024-08-07
US20160150768A1 (en) 2016-06-02
HUE061788T2 (hu) 2023-08-28
DK2604110T3 (en) 2017-02-13
JP2015126736A (ja) 2015-07-09
DK3028564T4 (da) 2024-04-22
EP2792236A3 (en) 2014-11-12
CY1126083T1 (el) 2023-11-15
DK2517556T4 (da) 2023-05-15
EP3028564B2 (en) 2024-01-24
AU2016244326B2 (en) 2018-04-26
US20140120582A1 (en) 2014-05-01
US11564380B2 (en) 2023-01-31
JP2020156503A (ja) 2020-10-01
EP3871497B1 (en) 2024-02-28
EP2564695A1 (en) 2013-03-06
DK3028565T3 (da) 2017-11-13
DK3241435T3 (da) 2021-08-23
EP3241435B1 (en) 2021-05-26
US20160044900A1 (en) 2016-02-18
KR20130042461A (ko) 2013-04-26
DK3028564T3 (da) 2017-11-13
JP2020028296A (ja) 2020-02-27
EP2792236B2 (en) 2023-03-22
US20170101482A1 (en) 2017-04-13
EP3622813B2 (en) 2024-06-19
EP3622814A1 (en) 2020-03-18
US10064398B2 (en) 2018-09-04
EP3028565B1 (en) 2017-09-27
EP3871498A1 (en) 2021-09-01
PL2517556T3 (pl) 2016-03-31
US20200337280A1 (en) 2020-10-29
DK2792236T3 (en) 2018-01-02
US20240057572A1 (en) 2024-02-22
WO2011004192A1 (en) 2011-01-13
US20140182003A1 (en) 2014-06-26
KR101875233B1 (ko) 2018-07-05
AU2010269978B2 (en) 2016-11-03
US20160345551A1 (en) 2016-12-01
ES2537239T3 (es) 2015-06-03
DK2564695T3 (en) 2015-05-26
EP3241435A1 (en) 2017-11-08
NZ597481A (en) 2013-10-25
EP3622815A1 (en) 2020-03-18
US20140201854A1 (en) 2014-07-17
JP6876854B2 (ja) 2021-05-26
AU2010269978A1 (en) 2012-02-02
JP6088562B2 (ja) 2017-03-01
US20140150125A1 (en) 2014-05-29
DK2798950T3 (en) 2017-05-22
ES2965212T3 (es) 2024-04-11
US20130042331A2 (en) 2013-02-14
ES2884309T3 (es) 2021-12-10
EP2517556A2 (en) 2012-10-31
HK1201026A1 (en) 2015-08-21
US20170099816A1 (en) 2017-04-13
EP3622815B1 (en) 2023-04-05
EP2798950B2 (en) 2023-03-22
EP2421357B1 (en) 2013-01-23
US10165763B2 (en) 2019-01-01
ES2948572T3 (es) 2023-09-14
HK1180535A1 (en) 2013-10-25
JP5944312B2 (ja) 2016-07-05
PT2421357E (pt) 2013-04-18
EP2792236B1 (en) 2017-11-15
US20170071174A1 (en) 2017-03-16
EP3622814C0 (en) 2023-11-08
EP2798950B1 (en) 2017-04-19
US20140201856A1 (en) 2014-07-17
JP2017086084A (ja) 2017-05-25
CA2767436A1 (en) 2011-01-13
JP6930695B2 (ja) 2021-09-01
US20200375158A1 (en) 2020-12-03
EP2517557A2 (en) 2012-10-31
PT3241435T (pt) 2021-08-26
HK1162119A1 (en) 2012-08-24
US20170051045A1 (en) 2017-02-23
DK3622813T3 (da) 2021-05-03
US20230263143A1 (en) 2023-08-24
US20160345552A1 (en) 2016-12-01
EP3871497A1 (en) 2021-09-01
DK2792236T4 (da) 2023-05-15
EP2517556B2 (en) 2023-03-22
US20120167237A1 (en) 2012-06-28
US20150334998A1 (en) 2015-11-26
US20230225302A1 (en) 2023-07-20
EP2564695B1 (en) 2015-04-15
EP3888457B1 (en) 2024-05-15
DK3028564T5 (da) 2024-04-29
US20150040250A1 (en) 2015-02-05
US9505827B2 (en) 2016-11-29
EP3028564B1 (en) 2017-09-27
CN102638971B (zh) 2015-10-07
SG177380A1 (en) 2012-02-28
US20200352145A1 (en) 2020-11-12
AU2021200079A1 (en) 2021-03-18
AU2018206729C1 (en) 2023-08-10
DK2517557T4 (da) 2023-09-25
EP2517556B1 (en) 2015-11-18
EP2517557A3 (en) 2013-07-24
EP2604110A2 (en) 2013-06-19
ES2403087T3 (es) 2013-05-14
EP3028565A1 (en) 2016-06-08
LT3241435T (lt) 2021-10-25
US9447177B2 (en) 2016-09-20
HRP20211253T1 (hr) 2021-11-12
EP3622813A1 (en) 2020-03-18
NO2792236T3 (ja) 2018-04-14
EP4014729A1 (en) 2022-06-22
US11606941B2 (en) 2023-03-21
EP2517556A3 (en) 2013-07-17
JP2020156502A (ja) 2020-10-01
SI3241435T1 (sl) 2021-11-30
EP3888457C0 (en) 2024-05-15
EP3622814B1 (en) 2023-11-08
EP2798950A1 (en) 2014-11-05
ES2557737T3 (es) 2016-01-28
JP2012532598A (ja) 2012-12-20

Similar Documents

Publication Publication Date Title
HK1202373A1 (en) Animal models and therapeutic molecules
HK1200872A1 (en) Animal models and therapeutic molecules
EP2426657A4 (en) ORGAN MODEL
GB0803018D0 (en) Therapeutic compounds and their use
EP2300011A4 (en) METHODS AND THERAPEUTIC COMPOUNDS
GB0804685D0 (en) Therapeutic compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
GB0918392D0 (en) Diagnostic and therapeutic methods
GB201103609D0 (en) Improvements in animal training and devices
EP2438167A4 (en) THERAPEUTIC AND DIAGNOSTIC MOLECULES
GB0812913D0 (en) Therapeutic compounds and their use
GB0911846D0 (en) Animal models and therapeutic molecules
GB0913102D0 (en) Animal models and therapeutic molesules
GB0802128D0 (en) Therapeutic compounds and their use
ES1071307Y (es) Carreton para entrenamiento en practicas de acoso-derribo y rejoneo
GB0913045D0 (en) Animal model
GB0913300D0 (en) Therapeutic compounds and their use
GB0921105D0 (en) Inhaler for humans and animals
AU2009900539A0 (en) Bacteriophage therapy in livestock

Legal Events

Date Code Title Description
AM43 Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance)